Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2015

Open Access 01-12-2015 | Review

Complement mediators: key regulators of airway tissue remodeling in asthma

Authors: Mohammad Afzal Khan, Abdullah Mohammed Assiri, Dieter Clemens Broering

Published in: Journal of Translational Medicine | Issue 1/2015

Login to get access

Abstract

The complement mediators are the major effectors of the immune balance, which operates at the interface between the innate and adaptive immunity, and is vital for many immunoregulatory functions. Activation of the complement cascade through the classical, alternative or lectin pathways thus generating opsonins like C3b and C5b, anaphylatoxins C3a and C5a, chemotaxin, and inflammatory mediators, which leads to cellular death. Complement mediators that accelerate the airway remodeling are not well defined; however, an uncontrolled Th2-driven adaptive immune response has been linked to the major pathophysiologic features of asthma, including bronchoconstriction, airway hyperresponsiveness, and airway inflammation. The mechanisms leading to complement mediated airway tissue remodeling, and the effect of therapy on preventing and/or reversing it are not clearly understood. This review highlights complement-mediated inflammation, and the mechanism through it triggers the airway tissue injury and remodeling in the airway epithelium that could serve as potential targets for developing a new drug to rescue the asthma patients.
Literature
1.
Hasegawa K, Tamari M, Shao C, Shimizu M, Takahashi N, Mao XQ et al (2004) Variations in the C3, C3a receptor, and C5 genes affect susceptibility to bronchial asthma. Hum Genet 115:295–301CrossRefPubMed
2.
Thangam EB, Venkatesha RT, Zaidi AK, Jordan-Sciutto KL, Goncharov DA, Krymskaya VP et al (2005) Airway smooth muscle cells enhance C3a-induced mast cell degranulation following cell-cell contact. FASEB J 19:798–800PubMed
3.
4.
Barnes PJ, Chung KF, Page CP (1998) Inflammatory mediators of asthma: an update. Pharmacol Rev 50:515–596PubMed
5.
Cho SH, Stanciu LA, Holgate ST, Johnston SL (2005) Increased interleukin-4, interleukin-5, and interferon-gamma in airway CD4+ and CD8+ T cells in atopic asthma. Am J Respir Crit Care Med 171:224–230CrossRefPubMed
6.
Huang TJ, MacAry PA, Kemeny DM, Chung KF (1999) Effect of CD8+ T-cell depletion on bronchial hyper-responsiveness and inflammation in sensitized and allergen-exposed Brown-Norway rats. Immunology 96:416–423PubMedCentralCrossRefPubMed
7.
Couto Alves A, Bruhn S, Ramasamy A, Wang H, Holloway JW, Hartikainen AL et al (2013) Dysregulation of complement system and CD4+ T cell activation pathways implicated in allergic response. PLoS One 8:e74821PubMedCentralCrossRefPubMed
8.
Lazaar AL, Panettieri RA Jr (2001) Airway smooth muscle as an immunomodulatory cell: a new target for pharmacotherapy? Curr Opin Pharmacol 1:259–264CrossRefPubMed
9.
Saglani S, Lloyd CM (2014) Eosinophils in the pathogenesis of paediatric severe asthma. Curr Opin Allergy Clin Immunol 14:143–148CrossRefPubMed
10.
Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P et al (2008) Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 38:709–750CrossRefPubMed
11.
12.
Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ (1999) Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 160:1532–1539CrossRefPubMed
13.
Hart PH (2001) Regulation of the inflammatory response in asthma by mast cell products. Immunol Cell Biol 79:149–153CrossRefPubMed
14.
Caramori G, Ito K, Adcock IM (2004) Targeting Th2 cells in asthmatic airways. Curr Drug Targets Inflamm Allergy 3:243–255CrossRefPubMed
15.
16.
Drouin SM, Kildsgaard J, Haviland J, Zabner J, Jia HP, McCray PB Jr et al (2001) Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J Immunol 166:2025–2032CrossRefPubMed
17.
Zhang X, Schmudde I, Laumonnier Y, Pandey MK, Clark JR, Konig P et al (2010) A critical role for C5L2 in the pathogenesis of experimental allergic asthma. J Immunol 185:6741–6752CrossRefPubMed
18.
Kohl J, Baelder R, Lewkowich IP, Pandey MK, Hawlisch H, Wang L et al (2006) A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J Clin Invest 116:783–796PubMedCentralCrossRefPubMed
19.
20.
21.
Mizutani N, Nabe T, Yoshino S (2009) Complement C3a regulates late asthmatic response and airway hyperresponsiveness in mice. J Immunol 183:4039–4046CrossRefPubMed
22.
Khan MA, Maasch C, Vater A, Klussmann S, Morser J, Leung LL et al (2013) Targeting complement component 5a promotes vascular integrity and limits airway remodeling. Proc Natl Acad Sci USA 110:6061–6066PubMedCentralCrossRefPubMed
23.
Krug N, Tschernig T, Erpenbeck VJ, Hohlfeld JM, Kohl J (2001) Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med 164:1841–1843CrossRefPubMed
24.
Olafsdottir IS, Gislason T, Thjodleifsson B, Olafsson I, Gislason D, Jogi R et al (2005) C reactive protein levels are increased in non-allergic but not allergic asthma: a multicentre epidemiological study. Thorax 60:451–454PubMedCentralCrossRefPubMed
25.
Mold C (1999) Role of complement in host defense against bacterial infection. Microbes Infect 1:633–638CrossRefPubMed
26.
Mold C, Gewurz H, Du Clos TW (1999) Regulation of complement activation by C-reactive protein. Immunopharmacology 42:23–30CrossRefPubMed
27.
Glovsky MM, Ward PA, Johnson KJ (2004) Complement determinations in human disease. Ann Allergy Asthma Immunol 93:513–522 (Quiz 523–515, 605) CrossRefPubMed
28.
Fayyazi A, Sandau R, Duong LQ, Gotze O, Radzun HJ, Schweyer S et al (1999) C5a receptor and interleukin-6 are expressed in tissue macrophages and stimulated keratinocytes but not in pulmonary and intestinal epithelial cells. Am J Pathol 154:495–501PubMedCentralCrossRefPubMed
29.
Rutkowski MJ, Sughrue ME, Kane AJ, Ahn BJ, Fang S, Parsa AT (2010) The complement cascade as a mediator of tissue growth and regeneration. Inflamm Res 59:897–905PubMedCentralCrossRefPubMed
30.
Lukacs NW, Glovsky MM, Ward PA (2001) Complement-dependent immune complex-induced bronchial inflammation and hyperreactivity. Am J Physiol Lung Cell Mol Physiol 280:L512–L518PubMed
31.
32.
Khan MA, Nicolls MR, Surguladze B, Saadoun I (2014) Complement components as potential therapeutic targets for asthma treatment. Respir Med 108:543–549PubMedCentralCrossRefPubMed
33.
Hawlisch H, Wills-Karp M, Karp CL, Kohl J (2004) The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol Immunol 41:123–131CrossRefPubMed
34.
Walters DM, Breysse PN, Schofield B, Wills-Karp M (2002) Complement factor 3 mediates particulate matter-induced airway hyperresponsiveness. Am J Respir Cell Mol Biol 27:413–418CrossRefPubMed
35.
Humbles AA, Lu B, Nilsson CA, Lilly C, Israel E, Fujiwara Y et al (2000) A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 406:998–1001CrossRefPubMed
36.
Kohl J, Wills-Karp M (2007) A dual role for complement in allergic asthma. Curr Opin Pharmacol 7:283–289CrossRefPubMed
37.
Banda NK, Hyatt S, Antonioli AH, White JT, Glogowska M, Takahashi K et al (2012) Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. J Immunol 188:1469–1478PubMedCentralCrossRefPubMed
38.
Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM (2000) Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 161:1720–1745CrossRefPubMed
39.
Clarke JR, Jenkins MA, Hopper JL, Carlin JB, Mayne C, Clayton DG et al (2000) Evidence for genetic associations between asthma, atopy, and bronchial hyperresponsiveness: a study of 8- to 18-yr-old twins. Am J Respir Crit Care Med 162:2188–2193CrossRefPubMed
40.
Lajoie S, Lewkowich IP, Suzuki Y, Clark JR, Sproles AA, Dienger K et al (2010) Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nat Immunol 11:928–935PubMedCentralCrossRefPubMed
41.
Stimler NP, Hugli TE, Bloor CM (1980) Pulmonary injury induced by C3a and C5a anaphylatoxins. Am J Pathol 100:327–348PubMedCentralPubMed
42.
43.
44.
Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS et al (2003) Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112:1029–1036PubMedCentralCrossRefPubMed
45.
Phipps S, Ying S, Wangoo A, Ong YE, Levi-Schaffer F, Kay AB (2002) The relationship between allergen-induced tissue eosinophilia and markers of repair and remodeling in human atopic skin. J Immunol 169:4604–4612CrossRefPubMed
46.
47.
Kelley J, Kovacs EJ, Nicholson K, Fabisiak JP (1991) Transforming growth factor-beta production by lung macrophages and fibroblasts. Chest 99:85S–86SPubMed
48.
Bergeron C, Tulic MK, Hamid Q (2010) Airway remodelling in asthma: from benchside to clinical practice. Can Respir J 17:e85–e93PubMedCentralPubMed
49.
Shifren A, Witt C, Christie C, Castro M (2012) Mechanisms of remodeling in asthmatic airways. J Allergy (Cairo) 2012:316049
50.
Reddy AT, Lakshmi SP, Reddy RC (2012) Murine model of allergen induced asthma. J Vis Exp (63):e3771
51.
Takeda K, Thurman JM, Tomlinson S, Okamoto M, Shiraishi Y, Ferreira VP et al (2012) The critical role of complement alternative pathway regulator factor H in allergen-induced airway hyperresponsiveness and inflammation. J Immunol 188:661–667PubMedCentralCrossRefPubMed
52.
Peng Q, Li K, Anderson K, Farrar CA, Lu B, Smith RA et al (2008) Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a-C3aR interaction. Blood 111:2452–2461CrossRefPubMed
53.
Peng T, Hao L, Madri JA, Su X, Elias JA, Stahl GL et al (2005) Role of C5 in the development of airway inflammation, airway hyperresponsiveness, and ongoing airway response. J Clin Invest 115:1590–1600PubMedCentralCrossRefPubMed
54.
Boulet LP, Turcotte H, Laviolette M, Naud F, Bernier MC, Martel S et al (2000) Airway hyperresponsiveness, inflammation, and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma. Influence of inhaled corticosteroids. Am J Respir Crit Care Med 162:1308–1313CrossRefPubMed
55.
Wust SK, Blumenthal MN, Corazalla EO, Benson BA, Dalmasso AP (2006) Complement in asthma: sensitivity to activation and generation of C3a and C5a via the different complement pathways. Transl Res 148:157–163CrossRefPubMed
56.
Baelder R, Fuchs B, Bautsch W, Zwirner J, Kohl J, Hoymann HG et al (2005) Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J Immunol 174:783–789CrossRefPubMed
57.
Fureder W, Agis H, Willheim M, Bankl HC, Maier U, Kishi K et al (1995) Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells. J Immunol 155:3152–3160PubMed
58.
Nilsson G, Johnell M, Hammer CH, Tiffany HL, Nilsson K, Metcalfe DD et al (1996) C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol 157:1693–1698PubMed
59.
DiScipio RG, Daffern PJ, Jagels MA, Broide DH, Sriramarao P (1999) A comparison of C3a and C5a-mediated stable adhesion of rolling eosinophils in postcapillary venules and transendothelial migration in vitro and in vivo. J Immunol 162:1127–1136PubMed
60.
Fischer WH, Jagels MA, Hugli TE (1999) Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(desArg). J Immunol 162:453–459PubMed
61.
Mathews JA, Wurmbrand AP, Ribeiro L, Neto FL, Shore SA (2014) Induction of IL-17A precedes development of airway hyperresponsiveness during diet-induced obesity and correlates with complement factor D. Front Immunol 5:440PubMedCentralCrossRefPubMed
62.
63.
Barnes PJ (1998) Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 94:557–572CrossRef
64.
Jatakanon A, Lalloo UG, Lim S, Chung KF, Barnes PJ (1999) Increased neutrophils and cytokines, TNF-alpha and IL-8, in induced sputum of non-asthmatic patients with chronic dry cough. Thorax 54:234–237PubMedCentralCrossRefPubMed
65.
Aksamit RR, Falk W, Leonard EJ (1981) Chemotaxis by mouse macrophage cell lines. J Immunol 126:2194–2199PubMed
66.
Ehrengruber MU, Geiser T, Deranleau DA (1994) Activation of human neutrophils by C3a and C5A. Comparison of the effects on shape changes, chemotaxis, secretion, and respiratory burst. FEBS Lett 346:181–184CrossRefPubMed
67.
Ottonello L, Corcione A, Tortolina G, Airoldi I, Albesiano E, Favre A et al (1999) rC5a directs the in vitro migration of human memory and naive tonsillar B lymphocytes: implications for B cell trafficking in secondary lymphoid tissues. J Immunol 162:6510–6517PubMed
68.
Nataf S, Davoust N, Ames RS, Barnum SR (1999) Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol 162:4018–4023PubMed
69.
Lett-Brown MA, Leonard EJ (1977) Histamine-induced inhibition of normal human basophil chemotaxis to C5a. J Immunol 118:815–818PubMed
70.
Hartmann K, Henz BM, Kruger-Krasagakes S, Kohl J, Burger R, Guhl S et al (1997) C3a and C5a stimulate chemotaxis of human mast cells. Blood 89:2863–2870PubMed
71.
Camous L, Roumenina L, Bigot S, Brachemi S, Fremeaux-Bacchi V, Lesavre P et al (2011) Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 117:1340–1349CrossRefPubMed
72.
He SH, Zhang HY, Zeng XN, Chen D, Yang PC (2013) Mast cells and basophils are essential for allergies: mechanisms of allergic inflammation and a proposed procedure for diagnosis. Acta Pharmacol Sin 34:1270–1283PubMedCentralCrossRefPubMed
73.
Fick RB Jr, Robbins RA, Squier SU, Schoderbek WE, Russ WD (1986) Complement activation in cystic fibrosis respiratory fluids: in vivo and in vitro generation of C5a and chemotactic activity. Pediatr Res 20:1258–1268CrossRefPubMed
74.
Murray LA, Argentieri RL, Farrell FX, Bracht M, Sheng H, Whitaker B et al (2008) Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2. Int J Biochem Cell Biol 40:2174–2182CrossRefPubMed
75.
Wills-Karp M, Koehl J (2005) New insights into the role of the complement pathway in allergy and asthma. Curr Allergy Asthma Rep 5:362–369CrossRefPubMed
76.
el-Lati SG, Dahinden CA, Church MK (1994) Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J Invest Dermatol 102:803–806CrossRefPubMed
77.
Takafuji S, Tadokoro K, Ito K, Dahinden CA (1994) Degranulation from human eosinophils stimulated with C3a and C5a. Int Arch Allergy Immunol 104(Suppl 1):27–29CrossRefPubMed
78.
Monsinjon T, Gasque P, Chan P, Ischenko A, Brady JJ, Fontaine MC (2003) Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 17:1003–1014CrossRefPubMed
79.
Arroyave CM, Stevenson DD, Vaughan JH, Tan EM (1977) Plasma complement changes during bronchospasm provoked in asthmatic patients. Clin Allergy 7:173–182CrossRefPubMed
80.
Lee SH, Rhim T, Choi YS, Min JW, Kim SH, Cho SY et al (2006) Complement C3a and C4a increased in plasma of patients with aspirin-induced asthma. Am J Respir Crit Care Med 173:370–378CrossRefPubMed
81.
Krug N, Erpenbeck VJ, Balke K, Petschallies J, Tschernig T, Hohlfeld JM et al (2001) Cytokine profile of bronchoalveolar lavage-derived CD4(+), CD8(+), and gammadelta T cells in people with asthma after segmental allergen challenge. Am J Respir Cell Mol Biol 25:125–131CrossRefPubMed
82.
Kew RR, Ghebrehiwet B, Janoff A (1987) Characterization of the third component of complement (C3) after activation by cigarette smoke. Clin Immunol Immunopathol 44:248–258CrossRefPubMed
83.
Stimler NP, Bloor CM, Hugli TE (1983) C3a-induced contraction of guinea pig lung parenchyma: role of cyclooxygenase metabolites. Immunopharmacology 5:251–257CrossRefPubMed
84.
Showell HJ, Glovsky MM, Ward PA (1982) C3a-induced lysosomal enzyme secretion from human neutrophils: lack of inhibition by f met-leu-phe antagonists and inhibition by arachidonic acid antagonists. Int Arch Allergy Appl Immunol 67:227–232CrossRefPubMed
85.
Becker S, Meuer S, Hadding U, Bitter-Suermann D (1978) Platelet activation: a new biological activity of guinea-pig C3a anaphylatoxin. Scand J Immunol 7:173–180CrossRefPubMed
86.
Baldo A, Sniderman AD, St-Luce S, Avramoglu RK, Maslowska M, Hoang B et al (1993) The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J Clin Invest 92:1543–1547PubMedCentralCrossRefPubMed
87.
88.
Fixman ED, Stewart A, Martin JG (2007) Basic mechanisms of development of airway structural changes in asthma. Eur Respir J 29:379–389CrossRefPubMed
89.
Aikawa T, Shimura S, Sasaki H, Ebina M, Takishima T (1992) Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest 101:916–921CrossRefPubMed
90.
Li X, Wilson JW (1997) Increased vascularity of the bronchial mucosa in mild asthma. Am J Respir Crit Care Med 156:229–233CrossRefPubMed
91.
Ameredes BT, Zamora R, Gibson KF, Billiar TR, Dixon-McCarthy B, Watkins S et al (2001) Increased nitric oxide production by airway cells of sensitized and challenged IL-10 knockout mice. J Leukoc Biol 70:730–736PubMed
92.
Cataldo D, Munaut C, Noel A, Frankenne F, Bartsch P, Foidart JM et al (2000) MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol 123:259–267CrossRefPubMed
93.
94.
Khan MA, Jiang X, Dhillon G, Beilke J, Holers VM, Atkinson C et al (2011) CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res 109:1290–1301PubMedCentralCrossRefPubMed
95.
Danobeitia JS, Djamali A, Fernandez LA (2014) The role of complement in the pathogenesis of renal ischemia-reperfusion injury and fibrosis. Fibrogenesis Tissue Repair 7:16PubMedCentralCrossRefPubMed
96.
Khan MA, Nicolls MR (2013) Complement-mediated microvascular injury leads to chronic rejection. Adv Exp Med Biol 734:233–246CrossRef
97.
98.
Ricklin D, Lambris JD (2013) Progress and trends in complement therapeutics. Adv Exp Med Biol 735:1–22CrossRef
Metadata
Title
Complement mediators: key regulators of airway tissue remodeling in asthma
Authors
Mohammad Afzal Khan
Abdullah Mohammed Assiri
Dieter Clemens Broering
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2015
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-015-0565-2

Other articles of this Issue 1/2015

Journal of Translational Medicine 1/2015 Go to the issue

Research

Rosuvastatin attenuates contrast-induced nephropathy through modulation of nitric oxide, inflammatory responses, oxidative stress and apoptosis in diabetic male rats

Research

Wnt signaling in age-related macular degeneration: human macular tissue and mouse model

Research

Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients

Research

Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma

Methodology

A workflow-driven approach to integrate generic software modules in a Trusted Third Party

Research

Quantitative analysis of proteins of metabolism by reverse phase protein microarrays identifies potential biomarkers of rare neuromuscular diseases
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits